… This analysis is intended to be a pragmatic cost-effectiveness analysis and firmly based
on observed prior clinical practice in Finland and on the operationalisation of the Finnish …

… ideal full adherence) on the cost-effectiveness of statin treatment in … Finnish setting.
This was done in an attempt to identify those patient groups for whom statin treatment is cost-effective …

… Finnish population. The objective of this study was to estimate the long-term incremental
cost-effectiveness … with simvastatin in the primary and secondary prevention of CHD in Finland. …

… in comparison to warfarin, but published evidence of relative cost-effectiveness between
DOACs … the cost-effectiveness of apixaban to dabigatran, rivaroxaban and warfarin in a Finnish …

… The support for cost-effectiveness was insensitive to … every year, the incremental cost-effectiveness
ratio did not show … The probabilistic sensitivity analysis indicated cost effectiveness in …

… cost of treatment would be lower if patients were started on PP-LAI rather than OLZ-LAI or
RIS-LAI. During 2010, RIS-LAI had the largest proportion of the market for LAIs in Finland, …

… The examples show that the Finnish PPS worsens the ICERs obtained for more … The
Finnish PPS is problematic when the aim is to provide Finnish patients with optimal, cost-effective …

… costs, cost-effectiveness (C/E), and patient-related C/E variances in THA and TKA from data
on 276 THA and 176 TKA patients. … was financially supported by the Academy of Finland. …

… the effect of bilat‐erality in survivorship or in cost‐benefit analyses. This fact may have had
an effect in our cost‐… operated patients. On the other hand, one‐stage bilaterally operated …

… lifetime cost of €187,776, while it was cost-effective against IV infliximab among biologic-naïve
patients … Secukinumab is a cost-effective treatment for PsA patients from a Finnish payer’s …